keyword
MENU ▼
Read by QxMD icon Read
search

bevacizumab colon cancer

keyword
https://www.readbyqxmd.com/read/29773991/first-biologic-drug-in-the-treatment-of-ras-wild-type-metastatic-colorectal-cancer-anti-egfr-or-bevacizumab-results-from-a-meta-analysis
#1
REVIEW
Alessandro Ottaiano, Alfonso De Stefano, Monica Capozzi, Anna Nappi, Chiara De Divitiis, Carmela Romano, Lucrezia Silvestro, Antonino Cassata, Rossana Casaretti, Salvatore Tafuto, Michele Caraglia, Massimiliano Berretta, Guglielmo Nasti, Antonio Avallone
Introduction: We performed a meta-analysis in order to analyze and quantify the effect on survival of starting therapy in RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients with anti-EGFR agents or bevacizumab. Patients and Methods: Randomized, phase II or III, clinical trials reporting overall survival (OS) in RAS wt mCRC patients treated with first-line chemotherapy (CT) associated with bevacizumab or anti-EGFR agents were selected. The primary end-point of this meta-analysis was OS; findings were depicted in classical Forest plots...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29763415/efficacy-safety-and-cost-of-therapy-of-the-traditional-chinese-medicine-catalpol-in-patients-following-surgical-resection-for-locally-advanced-colon-cancer
#2
Baogang Fei, Wei Dai, Shouhe Zhao
BACKGROUND The aim of this study was to evaluate the efficacy, safety, and cost of treatment of the traditional Chinese herbal medicine, catalpol, in patients following surgical resection for locally advanced colon cancer. MATERIAL AND METHODS The 345 patients who had undergone surgical resection for locally advanced colon adenocarcinoma, were divided into three groups: a placebo-treated group (n=115); patients treated with an intraperitoneal injection of 10 mg/kg catalpol twice a day for 12 weeks (treatment group) (n=115); patients treated with 5 mg/kg intravenous bevacizumab twice a week for 12 weeks (control group) (n=115)...
May 15, 2018: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/29755119/predictive-potential-of-tumour-stroma-ratio-on-benefit-from-adjuvant-bevacizumab-in-high-risk-stage-ii-and-stage-iii-colon-cancer
#3
Stéphanie M Zunder, Gabi W van Pelt, Hans J Gelderblom, Christoph Mancao, Hein Putter, Rob A Tollenaar, Wilma E Mesker
BACKGROUND: The tumour-stroma ratio (TSR) has proven to be an independent prognostic factor in colon cancer. METHODS: Haematoxylin eosin tissue slides of patients from the AVANT trial were microscopically scored for TSR and categorised as stroma -low or stroma -high. Scores were correlated to the primary and secondary endpoint disease-free survival (DFS) and overall survival (OS). RESULTS: Patients with stroma-high tumours (N = 339, 28%) had a significantly shorter DFS (p < 0...
May 14, 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29752549/promising-new-agents-for-colorectal-cancer
#4
REVIEW
Satya Das, Kristen K Ciombor, Sigurdis Haraldsdottir, Richard M Goldberg
Choosing the optimal treatment approach for patients with metastatic colorectal cancer (mCRC) demands that oncologists assess both clinical and genomic variables and individualize care based upon the findings. Clinically, choices depend on assessing the side of the colon in which the primary tumor originates, the sites and burden of metastatic disease, the patient's performance status, and their individual comorbidities. Genomic assessment of the tumor to discern the mutational status of genes such as RAS/RAF, HER2, and TRK, as well as assessing whether tumors have defective mismatch repair (dMMR) or high microsatellite instability (MSI-H), all factor in to potential treatment options and can determine clinical trial eligibility...
May 11, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29737958/increased-efficacy-of-stereotactic-ablative-radiation-therapy-after-bevacizumab-in-lung-oligometastases-from-colon-cancer
#5
Rosario Mazzola, Umberto Tebano, Dario Aiello, Gioacchino Di Paola, Niccolò Giaj-Levra, Francesco Ricchetti, Sergio Fersino, Alba Fiorentino, Ruggero Ruggieri, Filippo Alongi
Aim Metastases from colorectal cancer are poorly responsive to stereotactic ablative radiation therapy (SABR) due to intratumoral hypoxia. Intratumoral oxygenation is improved by administration of angiogenesis inhibitors. Thus, there could be a clinical synergistic effect of SABR with bevacizumab on metastases from colorectal cancer. The aim of this study was to evaluate the feasibility and efficacy of SABR after bevacizumab in lung oligometastases from colon cancer. Methods The data of patients with lung metastases from colon cancer who underwent SABR were retrospectively evaluated according to the following inclusion criteria: number of metastases ≤3; lung oligometastases from colon cancer in patients who underwent SABR; patients receiving previous chemotherapy alone or in combination with bevacizumab; Karnofsky performance status >80; life expectancy >6 months; at least 6 months' follow-up after SABR; presence of KRAS mutation...
December 1, 2017: Tumori
https://www.readbyqxmd.com/read/29650932/-a-case-of-sigmoid-colon-cancer-with-locally-advanced-infiltration-curatively-resected-after-capeox-therapy
#6
Yuki Suematsu, Mao Nakayama, Shunsuke Yamagishi, Hiroyuki Saito, Miyuki Takahashi, Kyohei Kanematsu, Michiko Fukabori, Kazuhiko Wakabayashi, Yutaka Itoh
A 68-year-old man presented with malaise and abdominal swelling.Lower gastrointestinal endoscopy revealed a type 2 circumferential sigmoid colon cancer.Computed tomography suggested the cancer infiltrating bladder and abdominal wall with abscess.Because of locally advanced infiltration, the patient was treated with capecitabine plus oxaliplatin(CapeOX) plus bevacizumab therapy after loop-colostomy.After 2 courses of chemotherapy, a CT revealed tumor reduction and increased abscess, which was punctured drainage...
March 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29650925/-a-case-of-colon-cancer-with-brain-liver-and-lung-metastasis-successfully-treated-with-bevacizumab-plus-xelox-therapy
#7
Tomokazu Tokoro, Keishi Nakamura, Atsushi Hirose, Shinichi Nakanuma, Kohichi Okamoto, Jun Kinoshita, Isamu Makino, Hironori Hayashi, Katsunobu Oyama, Tomoharu Miyashita, Hidehiro Tajima, Hiroyuki Takamura, Itasu Ninomiya, Sachio Fushida, Tetsuo Ohta
The patient was a 57-year-old woman. Preclinical examination of malignant lymphoma revealed 0-I sp type of early rectal cancer in the upper rectum, 20 cm from the anal margin. Endoscopic mucosal resection was performed and positive deep margins were pathologically diagnosed. Additional intestinal resection with lymph node dissection was deemed necessary, but ABVD therapy was initiated because the clinical stage of the malignant lymphoma was Stage III b or higher. Two months after detecting elevated CEA, S8 liver metastasis was pointed out, and examination of weakness of the right upper limb revealed nodular, multifocal brain metastasis...
March 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29650838/-two-cases-of-hepatic-encephalopathy-after-chemotherapy-for-metastatic-colorectal-cancer
#8
Tae Matsumura, Shingo Noura, Masaki Hirota, Yuki Ozato, Daiki Marukawa, Takashi Shuto, Arisa Muratsu, Akinobu Yasuyama, Akihiro Takata, Chikato Koga, Chizu Kameda, Masahiro Murakami, Ryohei Kawabata, Junzo Shimizu, Junichi Hasegawa
We reported 2 cases of hepatic encephalopathy after chemotherapy for advanced colorectal cancer. Case 1: A 49-year-old male was diagnosed advanced sigmoid colon cancer with peritoneal dissemination, multiple liver metastasis and multiple osseous metastasis. After resection of primary lesion, we administered mFOLFOX6 plus bevacizumab combination therapy. He was in comatose(Japan coma scale 200)3 days after 2 courses of administration of this regimen. Case 2: A 57-year-old female was diagnosed advanced rectal cancer with multiple huge liver metastasis and multiple osseous metastasis...
April 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29650827/-a-case-report-of-complete-resection-of-the-recurrence-small-intestinal-carcinoma-with-abdominal-wall-repair-using-femoral-fascia
#9
Tadafumi Fukata, Taishi Hata, Tateki Kubo, Naotsugu Haraguchi, Hidekazu Takahashi, Junichi Nishimura, Chu Matsuda, Tsunekazu Mizushima, Kou Hosokawa, Yuichiro Doki, Masaki Mori
The patients had Hartmann's operation for rectal cancer when she was 61 years old. After that, she underwent the operation for small bowel cancer when she was 68 years old. After 5 months, the only metastatic lesion was detected near the Scolon stoma. For the first therapy, She received chemotherapy(mFOLFOX6 plus bevacizumab)and had a reducing effect. She was introduced to our hospital for the purpose of resection of the recurrent lesion. CT scan detected a nodule near the Scolon stoma with FDG uptake for PET-CT scan...
April 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29580267/bevacizumab-induced-intestinal-perforation-in-a-patient-with-inoperable-breast-cancer-a-case-report-and-review-of-the-literature
#10
Yusuke Fujii, Noriyuki Hirahara, Syunsuke Kaji, Takahito Taniura, Ryoji Hyakudomi, Tetsu Yamamoto, Yoshitsugu Tajima
BACKGROUND: Gastrointestinal perforation is known as a serious adverse event, but, for breast cancer, there are very few reports of gastrointestinal perforation. This report highlights gastrointestinal perforation caused by bevacizumab for breast cancer, which is of special interest because gastrointestinal perforations caused by bevacizumab are very rare in breast cancer. CASE PRESENTATION: We describe the case of 54-year-old Japanese woman. She was diagnosed as having inoperable breast cancer T2 N1 M1 (pleura, peritoneum), Stage IV, and received chemotherapy by paclitaxel...
March 27, 2018: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29576428/c-met-overexpression-in-colorectal-cancer-a-poor-prognostic-factor-for-survival
#11
Su Jin Lee, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Young Suk Park, Seung Tae Kim
INTRODUCTION: Increased mesenchymal-epithelial transition factor gene (c-MET) expression in several human malignancies is related to increased tumor progression and is a new potential drug target for several types of cancers. In the present study, we investigated the incidence of c-MET overexpression and its prognostic significance in patients with colorectal cancer (CRC). PATIENTS AND METHODS: We retrospectively reviewed the data from 255 stage IV CRC patients who had results from a c-MET immunohistochemical test at Samsung Medical Center...
March 2, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29536229/clinical-predictors-of-bevacizumab-associated-intestinal-perforation-in-non-small-cell-lung-cancer
#12
Motohiro Tamiya, Hidekazu Suzuki, Takayuki Shiroyama, Ayako Tanaka, Naoko Morishita, Norio Okamoto, Kenichi Sakai, Hironori Shigeoka, Kunimitsu Kawahara, Tomonori Hirashima
Background Bevacizumab (Bev) is generally well-tolerated, and Bev-associated intestinal perforation (BAP) is a rare albeit serious side effect in cases of non-small cell lung cancer (NSCLC). Therefore, the present study aimed to identify clinical predictors of BAP to help predict and manage the development of life-threatening intestinal complications among patients receiving Bev. Methods This retrospective study evaluated demographic, clinical, and treatment factors for patients with NSCLC who were treated with Bev between February 2010 and August 2015 at our center...
March 14, 2018: Investigational New Drugs
https://www.readbyqxmd.com/read/29532881/vegf-pathway-targeting-drugs-induce-evasive-adaptation-by-activation-of-neuropilin-1-cmet-in-colon-cancer-cells
#13
Chisato Tomida, Naoko Yamagishi, Hikaru Nagano, Takayuki Uchida, Ayako Ohno, Katsuya Hirasaka, Takeshi Nikawa, Shigetada Teshima-Kondo
Anti-angiogenic therapies targeting vascular endothelial growth factor (VEGF) and its receptor (VEGF-R) are important treatments for a number of human malignancies, including colorectal cancers. However, there is increasing evidence that VEGF/VEGF-R inhibitors promote the adaptive and evasive resistance of tumor cells to the therapies. The mechanism by which the cancer cells become resistant remains unclear. One potential mechanism is that VEGF/VEGF-R blockers directly act on tumor cells independently of anti-angiogenic effects...
April 2018: International Journal of Oncology
https://www.readbyqxmd.com/read/29526944/posterior-reversible-encephalopathy-syndrome-after-a-variety-of-combined-chemotherapies-containing-bevacizumab-for-metastatic-colon-cancer
#14
Eiichi Katada, Akira Mitsui, Shigeru Sasaki, Norihiko Uematsu, Chise Anan
A 44-year-old woman with advanced metastatic colon cancer received chemotherapies comprising XELOX, FOLFIRI/panitumumab and mFOLFOX6/bevacizumab. Fifteen months later, she presented with the acute onset of a headache, drowsiness and seizure with a fever and hypertension. Brain magnetic resonance imaging (MRI) indicated bilateral regions of signal hyperintensity in the white matter with spasms of bilateral cerebral arteries apparent on magnetic resonance angiography. Posterior reversible encephalopathy syndrome (PRES) was diagnosed, and treatments resulted in improvement of the MRI findings, but the patient experienced cerebral infarction and ultimately died of deterioration of cancer on day 26 after the onset of PRES...
March 9, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29489644/a-case-report-of-limbic-encephalitis-in-a-metastatic-colon-cancer-patient-during-first-line-bevacizumab-combined-chemotherapy
#15
Laura Attademo, Stefano De Falco, Mario Rosanova, Marcello Esposito, Federica Mazio, Francesca Foschini, Antonio Santaniello, Giovanni Fiore, Elide Matano, Fiore Manganelli, Chiara Carlomagno
RATIONALE: Paraneoplastic limbic encephalitis (PLE) is one of the most common causes of neurologic paraneoplastic syndromes, with unclear pathogenesis. While several reports published in the last decades showed the occurrence of PLE in a variety of cancers, only a few cases have been associated with colon cancer. PATIENT CONCERNS: In February 2017, a 54-year-old man with clinical history of radically resected colon cancer started first line chemotherapy with FOLFOXIRI plus bevacizumab, after radiological diagnosis of multiple liver and bone metastases...
March 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29483433/-a-case-of-metastatic-colorectal-cancer-with-brain-metastasis-treated-with-combined-tftd-and-bevacizumab-therapy
#16
Jin Takano, Nobuhisa Matsuhashi, Takao Takahashi, Toshiyuki Tanahashi, Satoshi Matsui, Hisashi Imai, Yoshihiro Tanaka, Kazuya Yamaguchi, Kazuhiro Yoshida
A woman in her 70s was confirmed as presenting with multiple liver and lung metastases from transverse colon cancer. After undergoing resection of the primary lesion, partial response(PR)was achieved after undergoing the first regimen (sLV5FU2 and bevacizumab[Bmab]); therefore, partial hepatectomy was performed. Adjuvant chemotherapy was administered for 7 months, but liver metastasis recurrence, multiple lung metastases, and brain metastasis were confirmed. As the brain metastasis was a single lesion and was accompanied by symptoms, resection of the lesion was performed...
February 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29449515/-therapeutic-effects-of-low-dose-bevacizumab-for-the-treatment-of-recurrent-brain-metastases
#17
Etsuko Hattori, Akinori Miyakoshi, Kohichi Go, Toshiharu Aotake, Yoshiyuki Kawakami, Masato Sakamoto, Takeshi Kawauchi, Yuuki Oichi, Noritaka Sano, Makoto Hayase, Makoto Ohta, Yuki Hirose, Hiroki Toda
OBJECTIVE: Molecularly targeted therapy has been adopted to treat a number of cancers. Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor, is a representative agent used in molecularly targeted therapeutic regimens. However, the therapeutic effect of bevacizumab for the treatment of brain metastases remains unknown. We report the clinical effects of low dose bevacizumab(≤2.5mg/kg/week)to treat recurrent brain metastases. METHODS: We retrospectively analyzed patients with brain metastases who had been treated with bevacizumab between 2012 and 2016 at our institution...
February 2018: No Shinkei Geka. Neurological Surgery
https://www.readbyqxmd.com/read/29448309/the-value-of-additional-bevacizumab-in-patients-with-high-risk-stroma-high-colon-cancer-a-study-within-the-quasar2-trial-an-open-label-randomized-phase-3-trial
#18
Anouck Huijbers, Gabi W van Pelt, Rachel S Kerr, Elaine C Johnstone, Rob A E M Tollenaar, David J Kerr, Wilma E Mesker
INTRODUCTION: Patients with a high stroma percentage within the primary tumor have a poor prognosis. In this study, we investigate whether anti-angiogenic therapy might improve survival of patients with a stroma-high profile with potentially increased angiogenesis. MATERIALS AND METHODS: Tissue samples of the primary tumor of 965 colon cancer patients participating in the QUASAR2 trial were analyzed for tumor-stroma ratio (TSR). Stroma-high (>50%) and stroma-low (≤50%) groups were evaluated with respect to survival...
February 15, 2018: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29430222/long-term-colon-stent-patency-for-obstructing-colorectal-cancer-combined-with-bevacizumab
#19
Anouk E J Latenstein, Mathijs P Hendriks, Emo E van Halsema, Jeanin E van Hooft, Anne-Marie van Berkel
Self-expanding metal stents can be considered as initial treatment for malignant large bowel obstruction in the palliative setting. It is suggested that systemic anti-angiogenic therapy increases the risk of stent perforation. We report a 65-year-old woman with a metastatic, obstructing colon tumor who has been successfully treated with stent placement and chemoimmunotherapy consisting of capecitabine and bevacizumab for 8 years.
September 2017: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/29394784/-a-case-of-recurrent-colon-cancer-successfully-treated-with-capecitabine-plus-bevacizumab
#20
Atsushi Naito, Kohei Murata, Yoshinori Kagawa, Kenji Kawai, Takuya Sakamato, Junichi Inatome, Kohei Murakami, Yoshiteru Katsura, Yoshiaki Ohmura, Toru Masuzawa, Atsushi Takeno, Chiyomi Egawa, Yutaka Takeda, Takeshi Kato, Shigeyuki Tamura
A 76-year-old woman had undergone a laparoscopic low anterior resection for rectal cancer. After 12 months, CT showed 2 tumors measuring 25mm in diameter in the pelvis and hydronephrosis. The patient was treated with CapeOX plus bevacizumab( Bmab). After 3 courses of chemotherapy, the size of the tumors was remarkably reduced. After 6 courses, the chemotherapy was withdrawn because of cystitis. Anaphylactic shock occurred after the 7th course after resumption of treatment. After 42 days, the chemotherapy(Cape plus Bmab)was resumed...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
keyword
keyword
115852
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"